Tuesday, 22 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Finance
Clinical trial results
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14455
Articles
Company
Drug
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
December 2, 2024
Company
Drug
Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections
December 3, 2024
Company
Drug
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
December 2, 2024
Company
Deals
Next Generation Gene Therapeutics Secures $40 Million in Series B Financing for Gene Therapy Development
December 2, 2024
Company
Deals
Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan
December 2, 2024
Company
Drug
Hrain Biotechnology’s Anti-CD70 T Cell Therapy HR010 Gets Tacit Approval for Renal Cancer Trial
December 2, 2024
Company
Drug
Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China
December 2, 2024
Company
Deals
WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
December 2, 2024
Company
Drug
Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology
December 2, 2024
Company
Deals
Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs
December 2, 2024
Company
Drug
C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations
December 2, 2024
Policy / Regulatory
NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%
December 2, 2024
1
2
…
935
936
937
938
939
…
1,204
1,205
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?